Survodutide vs Retatrutide
How they differ
- FDA status, the same for both (In clinical trials). Survodutide: In clinical trials; not FDA-approved.1,2,3 Retatrutide: In clinical trials; not FDA-approved.3,4,5
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Survodutide | Retatrutide |
|---|---|---|
| What it is | An investigational glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, also known as BI 456906.1,6 | An investigational agonist of the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly and also known as LY3437943.4,7 |
| FDA status | In clinical trials In clinical trials; not FDA-approved1,2,3 Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.3 | In clinical trials In clinical trials; not FDA-approved3,4,5 Not FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.3 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.8 | Not among the six peptides the policy lists.8 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 13 ClinicalTrials.gov records and 4 PubMed records collected | 8 ClinicalTrials.gov records and 17 PubMed records collected |
| Area of study | ||
| Latest dated events |
|
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 3FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 4Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 5ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 6Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (2024) · PMID 38330987 ↗
The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026
- 7Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026) · PMID 42250575 ↗
The Lancet · Official source · Source checked November 14, 2026
- 8HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 9Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1, 2026) · PMID 42253238 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 10A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024) · PMID 38847460 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 11Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (2026) · PMID 42252333 ↗
Nature Medicine · Official source · Source checked November 14, 2026
- 12ClinicalTrials.gov record NCT06077864 · retained source version 2026-08-11:60e24ca2b3858aa7bfd06f0e1cac79051207229d8181cdbe15a0399bddf60984 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 13Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023) · PMID 37366315 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 14Retatrutide for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (2023) · PMID 37385280 ↗
The Lancet · Official source · Source checked November 14, 2026
- 15ClinicalTrials.gov record NCT05882045 · retained source version 2026-07-30:d21e38ddcccc7ab66ec1bddaa910bf3c7a7a3149a43f4ac27918a9e80f8452da ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 16ClinicalTrials.gov record NCT05929079 · retained source version 2026-07-30:d0cad2c0ebfa7ce1f2af088a52c397680123509e21999e7837a0b2b517e9ef04 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 17ClinicalTrials.gov record NCT06383390 · retained source version 2026-08-24:4bb37a90f79acd41fc8e0a5c8b4745c3c9610a0993eab8f502e836929a21c5ff ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026